Three acute treatments for migraine — Eli Lilly’s Reyvow (lasmiditan), Biohaven’s rimegepant, and Allergan’s Ubrelvy (ubrogepant) — may not be cost-effective, according to the Institute for Clinical and Economic Review (ICER).
The drug pricing watchdog compared the three treatments to approved triptans for cost-effectiveness and clinical benefit. While the costs of the new treatments are not yet known, ICER estimated that all three will be priced above GlaxoSmithKline’s triptan product Imitrex (sumatriptan succinate).
ICER found the three products were less cost-effective than sumatriptan and eletriptan for patients that can tolerate triptans. It also found the products weren’t cost-effective for patients intolerant of triptans. The institute said that the Eli Lilly, Biohaven and Allergan treatments offer “either a comparable or inferior net health benefit to triptans.”